Metabolic syndrome (MetS) is a multifaceted condition that increases the possibility of
developing atherosclerotic cardiovascular disease. MetS includes obesity, hypertension …

Cardiovascular disease is a leading cause of death and reduced quality of life worldwide.
Arterial vessels are a primary target for endothelial dysfunction and atherosclerosis, which is …

Objectives: This paper examined whether nebivolol protects the heart via nitric oxide (NO)
synthase and NO-dependent signaling in an in vivo model of acute myocardial infarction …

Aim To determine the safety and efficacy of nebivolol in elderly heart failure (HF) patients
with renal dysfunction. Methods and results SENIORS recruited patients aged 70 years or …

Despite progress in recent years in the prevention, detection, and treatment of high blood
pressure (BP), hypertension remains an important public health challenge. Hypertension …

Nebivolol is a racemic combination of d‐nebivolol (+ SRRR nebivolol) and l‐nebivolol (–
RSSS nebivolol) that differs chemically from other β‐blockers, with an absolutely …

Background This study was conducted to evaluate (i) the effect of nebivolol, a selective β1-
adrenergic receptor antagonist, on plasma concentration of asymmetric dimethylarginine …

Nebivolol is a third-generation β-adrenoceptor antagonist. It differs from other β-
adrenoceptor antagonists as it combines highly selective β 1-adrenoceptor antagonist …

Recent evidence supports additional subtypes of vasodilator β‐adrenoceptor (β‐AR)
besides the 'classical'β2. The aim of this study was to investigate the distribution of β‐ARs in …

Objective: TO describe the pharmacologic and pharmacokinetic properties of a new β-
adrenergic blocker, nebivolol, and review the literature evaluating its efficacy in the …